Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Powerful Medical
14. June 2024

Introducing PMcardio for Organizations: New Era in STEMI Patient Care

As a healthcare provider, you deliver timely, effective, and compassionate care in the high-stakes settings of emergency departments and cardiology units, managing complex cases under the constraints of limited resources and time pressures.

The High Stakes of Cardiac Care

Chest pain, the most common symptom in patients presenting to ED1, is at the heart of your clinical decision-making. Each year, over 50 million patients come to EDs with chest pain. With only 10% of these cases due to ACS1, identifying it can be like finding a needle in a haystack. However, with 4 million cases involving ACS1, the stakes are extraordinarily high, emphasizing the need for optimal patient outcomes.

Addressing Clinical Challenges Head-On

Managing ACS is highly challenging due to a 40% rate of false positive STEMI diagnoses, leading to unnecessary cath lab activations2 and underdiagnosis of acute coronary occlusions. One-third of patients presumed to be NSTEMI, actually suffer from occlusive coronary lesions requiring immediate interventions3. The oversight in this category includes failing to recognize STEMI-equivalent patterns, which, although not presenting with classic ST-elevation, still signify critical coronary artery occlusions.

The current rule-in pathway for early identification of STEMI patients is suboptimal, leading to frequent misidentification, wasted resources, and significant physician burnout. This inefficiency results in an average of $135,000 per year in canceled cath lab activation costs (assuming $1,500/cancellation) per mid-high volume center. Diagnostic inaccuracies expose patients to risks from unwarranted or delayed procedures, extend hospital stays, and worsen outcomes, with an average delay of 10.35 hours in time to coronary angiography and a doubling of the one-year all-cause mortality rate. Additionally, these issues strain healthcare resources and contribute to an 18.2% annual turnover rate among healthcare professionals4.

PMcardio for Organisation: Transformative Advances in Cardiac Medicine

PMcardio for Organizations is a diagnostic platform developed not just to serve as another tool in our kit but to revolutionize how you approach the chest pain patient’s journey from the moment they enter your facility. Designed by clinicians for clinicians, PMcardio is undergoing extensive validation by a network of over 35 leading international clinical research institutions and its effectiveness has been documented in more than 10 peer-reviewed medical publications

Introducing PMcardio for Organizations: New Era in STEMI Patient Care
An AI-powered platform enabling accurate diagnosis at first patient contact, ensuring rapid referral to cardiovascular specialists.

PMcardio harnesses the power of its OMI AI ECG Interpretation model, setting a new standard in the rapid assessment and triaging of chest pain patients, having screened over 400,000 ECGs since its launch and being utilized by more than 48,000 healthcare professionals worldwide.

Its impact was demonstrated at the Cardiovascular Centre Aalst in Belgium, among other sites, where the implementation of PMcardio achieved:

  • 68% reduction in false positive STEMI alerts and second opinion consultation requests
  • 100% sensitivity in true positive STEMI patients
  • 34% reduction in ECG to balloon time for STEMI patients, speeding up critical interventions
  • 50% decrease in door-to-ECG time month-over-month, with twice as many patients receiving ECG recordings within the guideline window
  • 56% decrease in door-to-balloon time for NSTEMI-OMI 
Introducing PMcardio for Organizations: New Era in STEMI Patient Care
Impact of Implementing PMcardio for Organization at the Cardiovascular Centre Aalst in Belgium.

PMcardio’s effectiveness is further validated by leading institutions:

  • Uniklinik Köln: Achieved 97% specificity in unselected all-comer chest pain patients without ST elevation
  • Cardiocentro Ticino, Lugano, Switzerland: Demonstrated a 73% positive predictive value in out-of-hospital cardiac arrest (OHCA) patients without ST elevation
  • SSM Health St. Louis University, MO: Showed twice the sensitivity compared to cardiologists
  • Hennepin County Medical Center, MN: Realized a 58% reduction in false positive cath lab activations
  • Stony Brook Medicine, NY: Attained 74% sensitivity in detecting acute OMI

These findings reveal how the platform can help you achieve more accurate diagnoses, streamline patient triage, and improve workflow processes.

Aligning Diagnostic Excellence Across the Board

Accurately diagnosing acute coronary occlusions is complicated by variable diagnostic skills and the rapidly evolving understanding of ECG patterns. Pattern recognition in ECG interpretation requires extensive hours of learning, which is often not feasible for physicians, especially emergency medicine doctors, who must stay proficient in many fields. As medical knowledge and diagnostic criteria evolve, keeping pace with advancements becomes increasingly challenging6

PMcardio addresses this need effectively by standardizing diagnostic processes using AI algorithms trained on over 2.5 million patient contacts across 32 geographically distinct locations. This training is designed to standardize care and minimize bias, making the PMcardio OMI AI ECG model robust across age, sex, and ethnic subgroups, while also ensuring transparency and explainability. 

At the optimal threshold, the PMcardio OMI AI ECG model exhibited a significantly higher sensitivity in identifying OMI compared with STEMI criteria, achieving 81% versus 32.5%5.

Introducing PMcardio for Organizations: New Era in STEMI Patient Care
Significantly higher sensitivity in identifying OMI compared with STEMI criteria, achieving 81% versus 32.5%5.

PMcardio offers a level of diagnostic security that outpaces even seasoned medical professionals. Despite initial concerns that the OMI paradigm shift might increase cath lab activations, the absolute number of activations is actually lower because many false positives are prevented. This means fewer unnecessary procedures, reduced patient risk, and more appropriate use of cath labs. Consequently, interventional cardiologists are only called for relevant patients.

Introducing PMcardio for Organizations: New Era in STEMI Patient Care

Optimize STEMI patient pathway with certified AI

The impact of PMcardio at the Cardiovascular Centre Aalst, Belgium:

Introducing PMcardio for Organizations: New Era in STEMI Patient Care
Introducing PMcardio for Organizations: New Era in STEMI Patient Care

Effective Triage that Speeds Up Diagnoses and Cath Lab Activations

PMcardio optimizes the triage process, significantly accelerating diagnoses and cath lab activations for critical cases from the first point of contact. The platform utilizes advanced ECG processing technology to substantially shorten the time from symptom onset to treatment by reducing the ECG to balloon time for STEMI patients by one-third. PMcardio makes it more attainable to meet the crucial 90-minute window from first medical contact as recommended by ACC/ESC/AHA guidelines to prevent irreversible myocardial damage7, contributing to a decrease in PCI time for patients with STEMI equivalents by an average of 10.3 hours, enhancing the efficiency of care5

As the platform enables immediate cardiology overreads, it further eliminates the delays traditionally associated with seeking second opinions or coordinating with cardiovascular specialists across the hospital.

Out-of-Hours Made Easier

PMcardio’s impact goes beyond daytime operations, addressing the high demands of out-of-hours cath lab activations. By significantly reducing false positive STEMI alerts and unnecessary activations, it minimizes callouts and optimizes cath lab resources. This efficiency allows healthcare staff to focus on real emergencies.

PMcardio’s mobile accessibility enables healthcare professionals to access ECG data and make decisions remotely, even from home. This flexibility ensures continuity of care during out-of-hours, potentially increasing rest periods and reducing burnout among medical teams, leading to a more balanced workload and improved well-being for hospital staff.

Empowering Nursing Staff

PMcardio’s all-in-one design maximizes accessibility and efficiency, as it is readily available on various devices such as smartphones and tablets. This mobility ensures that critical patient information and diagnostic tools are always at the nurses’ fingertips, no matter where they are in the hospital. This not only accelerates the decision-making process but also bolsters nurses’ competence, enabling them to act decisively and confidently. By enhancing their responsiveness in critical situations, PMcardio aims to improve patient advocacy and reinforce nurses’ empowerment in their clinical roles.

Introducing PMcardio for Organizations: New Era in STEMI Patient Care
A critical diagnostic tool that is always within reach.

Streamlining Workflows

Effective communication among nurses, emergency medicine physicians, and cardiologists is essential, yet often challenged by the fast-paced, high-stress environment of emergency care and varying clinical perspectives. PMcardio for Organizations offers a personalized and unified care-coordination platform that delivers real-time diagnostic interpretations accessible to the entire team. This shared platform supports simultaneous access for improved decision-making, promoting quick alignment on treatment strategies and speedy referrals.

The flexibility of PMcardio for Organizations allows it to be tailored to the specific needs of each team member, whether on a personal, ward-specific, or institutional level. It can be configured to match the unique workflows of different departments, ensuring that the ECG review process is as smooth as possible, regardless of the clinical setting. 

A Tool That Understands Clinical Needs

Developed with direct input from seasoned medical professionals, PMcardio addresses the real-world complexities of managing chest pain in a high-pressure environment. It doesn’t just add to the noise; it cuts through it with precision and speed, enhancing your capabilities and allowing you to focus more on what matters most – patient care.

Introducing PMcardio for Organizations: New Era in STEMI Patient Care
Enterprise-level functionalities that enable safe and integrated patient management.

Commitment to Privacy and Clinical Excellence 

PMcardio for Organizations allows for precise diagnostic assessments based solely on ECG data, without the need to identify the patient. While the secure platform stores ECG records to support ongoing management, it ensures that personal patient details remain confidential, prioritizing privacy alongside effective clinical decision-making in full compliance with security and privacy regulations8. The platform also features enterprise-level functionalities that enable safe and integrated patient management, including central report management through a single admin dashboard, where all ECGs within your organization can be accessed and reviewed.

Additionally, PMcardio for Organizations enhances the capabilities of your team to detect trends, refine treatment protocols, and support educational activities. Implement this tool in your preparations for mortality and morbidity meetings, participation in grand rounds, and during discussions at quality improvement and clinical governance meetings to make your sessions more data-driven and effective.

As you embark on this new era in STEMI patient care with PMcardio for Organizations, the platform stands as your partner in mastering the complexities of modern healthcare, ensuring that every patient benefits from top-tier, timely care.

Book a Demo to see how PMcardio for Organizations can transform chest pain patient’s journey at your facility.

Introducing PMcardio for Organizations: New Era in STEMI Patient Care
Introducing PMcardio for Organizations: New Era in STEMI Patient Care

Stay on the pulse with our newsletter

Your submission was successful

References

  1. Rui P, Kang K. National Hospital Ambulatory Medical Care Survey: 2017 emergency department summary tables. National Center for Health Statistics. Available from https://www.cdc.gov/nchs/data/nhamcs/web_tables/2017_ed_web_tables-508.pdf.
  2. Larson DM, Menssen KM, Sharkey SW, et al. “False-Positive” Cardiac Catheterization Laboratory Activation Among Patients With Suspected ST-Segment Elevation Myocardial Infarction. JAMA. 2007;298(23):2754-2760. doi:10.1001/jama.298.23.2754.
  3. Khan AR, Golwala H, Tripathi A, Bin Abdulhak AA, Bavishi C, Riaz H, et al. Impact of total coronary occlusion on outcomes of patients with non-ST-elevation myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis. Eur Heart J. 2017 Dec 21;38(43):3082-3089. doi: 10.1093/eurheartj/ehx391. PMID: 29020244.
  4. Taking the Heart Team Staffing Business Seriously. Diagnostic and Interventional Cardiology. Available from: https://www.dicardiology.com/article/taking-heart-team-staffing-business-seriously
  5. Herman R, Smith SW, Meyers HP, Bertolone DT, Leone A, Bermpeis K, et al. Poor prognosis of total culprit artery occlusion in patients presenting with NSTEMI. Eur Heart J. 2023 Nov;44(Suppl_2):ehad655.1536. doi: 10.1093/eurheartj/ehad655.1536.
  6. Wagner GS, Macfarlane P, Wellens H, Josephson M, Gorgels A, Mirvis DM, et al. AHA scientific statement: standardization and interpretation of the electrocardiogram. J Am Heart Assoc. 2013 Jul 24;2(4):e000268.
  7. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Nov 30;144(22):e368-e454. doi: 10.1161/CIR.0000000000001029. Epub 2021 Oct 28. Erratum in: Circulation. 2021 Nov 30;144(22):e455. Erratum in: Circulation. 2023 Dec 12;148(24):e281. PMID: 34709879.
  8. Powerful Medical. Available from: https://www.powerfulmedical.com

Powerful Medical

Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.
About PMcardio:

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical:

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Don't miss these

Powerful Medical team receiving the MedTech Innovator 2025 Mid-Stage Grand Prize award on stage, holding a large winner’s check.

Powerful Medical Wins MedTech Innovator 2025

Powerful Medical has been named MedTech Innovator 2025, winning MTI’s Mid-Stage Grand Finals—top honor from the world’s largest medtech accelerator. The award recognizes PMcardio and its FDA Breakthrough-designated Queen of Hearts™ AI ECG technology, which doubles sensitivity for detecting severe heart attacks and significantly cuts ECG-to-balloon time in large clinical trials.

PMcardio Reports Positive RCT Results and Late-Breaking Clinical Science for STEMI Detection

PMcardio’s AI-powered ECG technology delivers breakthrough results at TCT 2025—improving heart attack detection, reducing false activations, and enabling faster treatment across major clinical trials, including the landmark DIFOCCULT-3 RCT.

Join over 100,000 healthcare professionals who are already taking advantage of AI

Suites

Five suites.
One platform.
The full cardiac care journey.

PMcardio’s clinical suites cover the full spectrum of cardiac care — from acute emergency detection to longitudinal monitoring. Deploy the suites that match your priorities today, expand as your needs grow.

Minutes matter

Acute Care Suite

AI-powered detection and pathway coordination for time-critical cardiac events — including STEMI and OMI, pulmonary embolism / RV strain, and hyperkalemia.

  • stemi/OMI
  • pe/RV strain
  • hyperK

Find what ECGs Hide

Echo Screening Suite

AI-powered screening for structural heart disease directly from a 12-lead ECG — detecting reduced LVEF, aortic stenosis, HCM, and other SHD conditions that traditional ECG interpretation misses.

  • lvef
  • aortic stenosis
  • hcm

Ambulatory, automated

Remote Monitoring Suite

AI-powered analysis of ambulatory ECG recordings — Holter monitors, cardiac patches, and other continuous monitoring devices — with automated findings and longitudinal tracking.

  • holter
  • cardiac patches
  • arrhythmia burden

Beyond the clinic

Patient Suite

AI-powered ECG interpretation for consumer wearables and patient-facing devices — extending cardiac care beyond the clinic into everyday life.

  • wearable ECG Analysis
  • PPG Analysis

On-table intelligence

Angio Suite

AI-powered analysis of coronary angiography — automated stenosis quantification, TIMI frame count, guide wire detection, and myocardial blush grading in near real-time.

  • vessel segmentation
  • stenosis quant.
  • timi frames
  • blush grading

Governance, customization & configuration

Align the platform to your protocols — without a custom software project.

Configure escalation thresholds, roles, and reporting to match local pathway rules — while maintaining system-wide governance and consistency.

  • Configurable triggers, roles, and escalation workflows
  • Custom dashboards and views aligned to leadership needs
  • Controlled expansion to additional pathways over time

Outcomes, QA & performance intelligence​

Measure what matters — across every pathway, every site.

Turn pathway execution into dashboards and reporting that help leadership reduce variation, optimize time-to-treatment, and demonstrate value across every deployed suite.

  • Cross-site, cross-pathway, and team-level benchmarking
  • Time-to-treatment and pathway quality tracking
  • QA workflows, audit trails, and leadership reporting
  • Registry-aligned reporting support (NCDR Chest Pain-MI, AHA GWTG, and more)

Escalation & care coordination

Real-time routing that matches how your system actually runs.

Route critical cases to the right team with role-based notifications, escalation logic, and shared case context — across EMS, ED, cardiology, cath lab, and inpatient care.

  • Role-based alerting and escalation across departments and sites
  • Shared case context so receiving teams have what they need before the patient arrives
  • Integration with existing communication and alerting tools

AI-powered decision support

Clinically validated AI that spans the cardiac care journey.

Run multiple AI models on every recording — acute detection, screening, procedural quantification — with interpretable outputs and case-level explainability.

  • Queen of Hearts™ for STEMI/OMI detection
  • LVsense™ for reduced ejection fraction
  • Culprit Artery Prediction for pre-cath planning
  • Core AI for comprehensive rhythm and conduction analysis
  • Expanding model portfolio across Echo Screening, Remote Monitoring, and Angio Suites

Interoperability & deployment

Connect across your existing systems — without replacing them.

Ingest pathway-critical inputs from across your network and IT landscape, and deliver results where teams already work. Built for system-wide rollout with enterprise deployment patterns.

  • Connect to ECG devices, angiographic systems, and ambulatory monitors across sites
  • Launch PMcardio from the EHR / CVIS with secure links and SSO
  • Send results back to clinical systems where care is documented

All Supported ECG Findings

Rhythms
Sinus bradycardia • Sinus rhythm • Sinus tachycardia • Paced rhythm • Atrial fibrillation
Atrial fibrillation with rapid ventricular response • Atrial fibrillation with slow ventricular response • Atrial flutter • Atrial flutter with rapid ventricular response • Atrial flutter with slow ventricular response • Supraventricular tachycardia • Suspected junctional rhythm • Suspected junctional bradycardia • Suspected accelerated junctional rhythm • Wide QRS rhythm • Idioventricular rhythm • Wide QRS tachycardia

Myocardial Infarctions
  • STEMI
  • STEMI
    Equivalent
Detects occlusive myocardial infarctions (OMIs) even without ST elevation (i.e. posterior STEMI, hyperacute T-waves, etc.). Negative for STEMI mimics (i.e. early repolarization, LVH, etc.)
  • High-Risk NSTEMI
    Represents a type 1 myocardial infarction caused by a transiently recanalized coronary occlusion—classically seen in patterns such as Wellens type A or B due to subtotal LAD obstruction, but possible in any infarct-related territory.
  • Culprit Detection
    AI-predicted likelihood scores for LAD, LCx, and RCA with 3D heart visualization highlighting the predicted culprit artery.

Conduction Abnormalities (Heart Blocks
1st degree AV block • 2nd degree AV block, type Wenckebach • Higher degree AV block • Complete right bundle branch block • Incomplete right bundle branch block • Complete left bundle branch block • Incomplete left bundle branch block • Nonspecific intraventricular conduction delay • Left anterior fascicular block • Left posterior fascicular block • Bifascicular block (RBBB + LAFB) • Bifascicular block (RBBB + LPFB) • Trifascicular block (RBBB + LAFB + AVBLOCK1) • Trifascicular block (RBBB + LPFB + AVBLOCK1)

LVEF
Reduced LVEF (≤40%) • Mildly reduced LVEF (41 – 49%) • No signs of reduced LVEF (≥50%)

Axis
Left cardiac axis deviation • Right cardiac axis deviation • Extreme cardiac axis deviation • Normal axis

Measurements
Heart rate • P wave • PR interval • QRS duration • QT interval • Corrected QT interval (Framingham formula) • RR interval • PP interval • ST elevations

Other Supported Diagnoses
Suspected long QT syndrome • Suspected short QT syndrome • Suspected atrial enlargement • Suspected ventricular hypertrophy • Premature complexes

Dr. Tom De Potter, MD

Cardiologist at the Cardiac Center Aalst

Cardiologist specializing in Pacemaker Device Therapy and Electrophysiology. Leads the electrophysiology unit at the Heart Center in Aalst, holds an executive board position at the European Heart Academy, and serves as EHRA scientific program committee co-chair.

Dr. Martin Penicka, MD, PhD

Cardiologist at the Cardiac Center Aalst

Cardiologist at the Cardiac Center Aalst since 2009, specializing in non-invasive imaging and valvular disease. Fellow of the European Society of Cardiology (FESC) and the European Association of Cardiovascular Imaging (FEACVI).

Dr. Ward Heggermont, MD, PhD

Co-director at the Cardiovascular Center

Co-director at the Cardiovascular Center of Aalst Hospital, specializing in heart failure. Research focus at the intersection of cardiology, virology, and metabolism.

Prof. Dr. Robert Hatala, PhD

Co-founder and Chief Scientist

Head of the Arrhythmia and Pacing department at the National Institute of Cardiovascular Diseases in Slovakia. More than 150 publications and 10,000 citations. Contributor to ESC clinical practice guidelines and executive editor of the European Heart Journal since 2020.

Arieh Levy

Head of PMcardio for Individuals

Arieh leads the PMcardio for Individuals product at Powerful Medical, guiding its development as a clinical tool for emergency physicians, cardiologists, and primary care physicians. He holds a First Class MEng in Biomedical Engineering from Imperial College London, where he specialised in AI for cardiology, building physics-informed neural networks to model atrial electrical properties, giving him a background that bridges the clinical and technical demands of building a certified AI medical device used at the bedside every day.

Dr. Dave Pearson, MD​

Business Advisor

Academic emergency medicine physician, entrepreneur, investor, and researcher with nearly two decades at Atrium Health, one of US largest health systems. Brings expertise at the intersection of clinical care, healthcare innovation, and strategic leadership.

Prof. Stephen W. Smith, MD

Professor of Emergency Medicine

Faculty physician in Emergency Medicine at Hennepin County Medical Center and Professor of Emergency Medicine at the University of Minnesota. Co-inventor of the OMI paradigm and editor of Dr. Smith’s ECG Blog, the most-visited US-based ECG interpretation blog.

Prof. Emanuele Barbato, MD, PhD

President of EAPCI

Interventional cardiologist specializing in coronary artery disease and coronary physiology. Acting president of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and contributor to the clinical practice guidelines for STEMI care.

Scott Sharkey, MD

Chief Medical Officer

Chief Medical Officer of the Minneapolis Heart Institute Foundation and practicing cardiologist at Allina Health Minneapolis Heart Institute. Co-founder of the STEMI Midwest consortium and Takotsubo cardiomyopathy research program and a widely published clinical investigator in STEMI care.

Prof. Dr. Leor Perl, MD

Director of Cardiac Catheterization Institute

Director of Complex Cardiac Interventions and Chief Innovation Officer at Rabin Medical Center. Graduate of the Stanford Biodesign Program.

Suzanne J. Baron, MD, MSc

Director of Interventional Cardiology Research

Director of Interventional Cardiology Research at Massachusetts General Hospital. Holds a Master’s degree in health economics from Harvard School of Public Health. Expert in cardiovascular device impact on healthcare costs and patient-reported outcomes.

Prof. Marco Valgimigli, MD

Deputy Chief Cardiocentro Ticino Institute

Head of Cardiology at Cardiocentro Ticino and Principal Investigator of the TITAN-OMI randomized controlled trial. His research has shaped both European and US clinical practice guidelines on coronary stents, antithrombotic therapy, and vascular access.

Timothy D. Henry, MD

Medical Director of The Carl and Edyth Lindner Center

Leading expert in interventional cardiology and STEMI treatment. Co-founder and principal investigator of the Midwest STEMI Consortium, a registry of more than 20,000 consecutive STEMI activations. Presenting author for the TCT 2025 Late-Breaking Clinical Science on Queen of Hearts.

Matus Horvath

Head of People

Matus leads hiring strategy and culture at Powerful Medical. He previously ran the People Team at Slido, the Slovak SaaS startup later acquired by Cisco — an experience that informs how he builds a high-performing, values-driven team through rapid scaling.

Dr. Timea Kisova, MD

Clinical Research Lead

Timea leads Powerful Medical’s global external validation studies, including the multi-country AI ECG TIMI Study. With a background in biomedical sciences and a medical degree from Barts and The London School of Medicine and Dentistry, she brings the clinical discipline required to generate the prospective, real-world evidence behind every PMcardio module.

Dr. Anthony Demolder, MD, PhD

HF Pathway Lead

Research physician with a PhD on arrhythmias in heritable thoracic aortic disease. He has led international studies at the intersection of cardiology and AI — including earlier work on atrial fibrillation at AZ Sint-Jan Brugge — and now drives Powerful Medical’s heart failure pathway and LVsense™ AI model development.

Dr. Pendell Meyers, MD

ACS Pathway Lead

Emergency medicine physician, prolific educator, and Co-Editor of Dr. Smith’s ECG Blog. He is one of the leading voices behind the Occlusion Myocardial Infarction (OMI) paradigm, the clinical framework that reshaped how heart attacks are identified from the ECG — and which sits at the core of the Queen of Hearts™ model.

Adam Dej

Head of PMcardio for Organizations Engineering

Adam leads engineering for PMcardio for Organizations at Powerful Medical, driving platform architecture, backend systems, and infrastructure behind one of the company’s key growth products. He began programming at 13, entered professional IT at 17, and studied computer security at Comenius University’s Faculty of Mathematics, Physics and Informatics. Known for technical depth across distributed systems, infrastructure, and security, he builds scalable and resilient software with a sharp focus on customer impact. He also champions responsible use of AI and LLMs as force multipliers for modern engineering teams.

Gabriela Rovder Sklencarova

Head of Infrastructure

Gabriela designs the scalable, secure, distributed systems that keep PMcardio running around the clock for clinicians worldwide. She joined from Google, where she was a senior software engineer building core libraries that kept Google’s services resilient against billions of requests, and holds a BA and MA in Computer Science from the University of Cambridge.

Arezou Azar

US and Global Regulatory

Arezou leads Powerful Medical’s global regulatory strategy across the FDA, EU MDR, and international frameworks. She has been part of nearly every major breakthrough in AI cardiology and is an expert in US and global regulatory strategy, SaMD/digital health launches, with experience at Eko Health, Verily, AliveCor, Cardiologs, and Apple. She specializes in regulatory strategy in high-paced global organizations.

Adam Rafajdus

Head of AI

Adam grew into the Head of AI role from MLOps Engineer over six years at Powerful Medical, bringing deep expertise in deep learning and production-grade system deployment. He leads the team behind the Queen of Hearts™ AI ECG models and was awarded Best Poster at ISCE 2025 for the company’s ECG digitization pipeline.

Mike Wall

VP of Sales

Mike brings more than twenty years at UnitedHealth Group to the table, where he served health plans, employer groups, and public-sector entities as a consultative healthcare sales executive. He combines market intelligence, clinical insight, and financial acumen — the three ingredients needed to bring AI-powered diagnostics into US health systems at scale.

Amani Farid

Head of Strategic Partnerships

Amani leads partnership strategy with a hands-on approach to integration, unlocking long-term value through collaboration and scale. A University of Chicago Law School-trained attorney and former M&A and capital markets associate at two top international law firms, she brings the rare combination of legal precision and commercial execution refined across nearly a decade at Stryker and as VP of Corporate Development at RapidAI — spanning medtech, digital health, and AI-driven diagnostics.

Michal Martonak

Commercial Lead

A mathematician by training, Michal leads commercial strategy, go-to-market, and strategic partnerships with healthcare providers and clinical institutions worldwide. He previously built Powerful Medical’s data and clinical partnerships function, acquiring the large-scale clinical datasets that underpin the company’s certified AI models.

Dr. Jozef Bartunek, MD, PhD

Co-founder and VP Clinical Strategy

Interventional cardiologist and Co-director of the Cardiovascular Center in Aalst, Belgium — one of the world’s leading heart centers. A Fogarty International NIH Fellow at Harvard Medical School and visiting Professor of Medicine at Catholic University Leuven, he has authored more than 240 peer-reviewed publications in heart failure and structural heart disease, and anchors Powerful Medical’s clinical and research strategy.

Simon Rovder

Co-founder and CTO

Simon began his engineering career at Microsoft and holds a Master’s degree in Informatics from the University of Edinburgh. He built and scaled Powerful Medical’s technology organization from the ground up to a team of 20+ engineers, leading the architecture of a CE-certified Class IIb medical device now deployed in hospitals across Europe.

Viktor Jurasek

Co-founder and CPO

Viktor was modding computer games before his teens and has spent the last decade shipping digital products across advertising, finance, and healthcare. As co-founder and CPO, he has led PMcardio’s product and design since the first prototype, setting the bar for how a clinical-grade tool should feel in a physician’s hands — fast, clear, and trustworthy at the point of care.

Felix Bauer

Co-founder and COO

Felix was part of the Hyperloop team that repeatedly competed and won in Elon Musk’s SpaceX Hyperloop Pod Competition. He holds a degree from the Technical University of Munich and brings a rare combination of engineering rigor, regulatory discipline, and operational excellence to the company, spearheading operations, compliance, regulatory, quality management, and global market access since day one.

Dr. Robert Herman, MD, PhD

Co-founder and Chief Medical Officer

Robert is a physician-scientist who served on the Research, Digital and Innovation Committee of the European Society of Cardiology. He bridges medicine and AI, connecting clinicians, researchers, regulators, and trial leaders to translate algorithms into clinical practice. He founded multiple AI ECG models, leads international clinical trials validating them, is a recipient of the Journal of the American College of Cardiology Spencer King Award, and was named to Forbes 30 Under 30 Europe 2024.

Martin Herman

Co-founder and CEO

Martin started coding at 14 and moved to Silicon Valley at 18, founding several companies including a US-based startup before returning to Europe with his brother Robert to build Powerful Medical. He comes from a family of doctors, which shaped his conviction that AI belongs wherever it can genuinely save lives. Forbes 30 Under 30 (Europe 2024).

Heart Attacks are #1 cause of death world-wide and killing about 12 milions people a year.

Clinical Definition of Problem

Contrary to popular belief, a heart attacks isn’t a blockage inside of the heart. A heart attack is a blockage of the coronary arteries supplying the heart muscle with oxygenated blood.

So let’s assume you get a blood clot here — it blocks the blood flow downstream, meaning the heart muscle doesn’t get oxygenated blood and heart tissue downstream starts to die.

Clinical Solution​

The way to fix it is relatively simple – doctors put in a stent that opens up the artery and renews blood flow. The latest clinical practice guidelines recommend that this “stenting” happens within 90 minutes from symptom onset.

If you don’t, even if you put in the stent in later, the heart tissue downstream has already been permanently damaged, which reduces the heart’s ability to pump blood. This is the leading cause of heart failure and increases 1-year mortality by two-fold.

Time is muscle.

You have just 90 minutes to diagnose the patient, bring them to the hospital and put in the stent, otherwise there is permanent damage. So problem is, that 1 in 2 heart attacks get initially misdiagnosed at the first point of contact.

Discover the future of medical work with us.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.